Arch Iran Med. 2019;22(12): 692-698.
PMID: 31823620
Scopus ID: 85076351054
  Abstract View: 2185
  PDF Download: 1474

Original Article

Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy

Ali Rabiey 1, Peyman Hassani-Abharian 2, Majid Farhad 1, Ali Reza Moravveji 3, Goodarz Akasheh 4, Hamid Reza Banafshe 5,6*

1 Department of Addiction Studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran
2 Institute for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran
3 Department of Community Medicine, Kashan University of Medical Sciences, Kashan, Iran
4 Department of Psychiatry, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
5 Department of Pharmacology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
6 Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
*Corresponding Author: Email: Banafshe57@hotmail.com


Background: Co-occurring methamphetamine (METH) use during methadone maintenance therapy (MMT) is a highly prevalent and progressive problem in Iran. There are no registered pharmacological treatments for treating METH use disorder. The present study investigates the potential efficacy of atomoxetine in the treatment of these patients.

Methods: In a double-blind, controlled clinical trial, 86 METH-dependents on MMT randomly received either atomoxetine (40 mg/d) or placebo. We measured the craving scores with visual analog scale (VAS) on a weekly basis, and evaluated depression, anxiety and stress with the Depression Anxiety Stress Scales (DASS) on a monthly basis. Measurements were made in each weekly visit with urinary METH drug test.

Results: Atomoxetine significantly reduced METH craving (P<0.001). Negative METH urine test increased significantly in the drug group compared to the placebo group (P = 0.007). While initially the METH urine test was positive for all patients, 56% (25/45) in the atomoxetine group and 26% (11/41) in the placebo group had negative METH urine tests after 8 weeks. DASS were decreased in both groups with a greater reduction in the atomoxetine group [depression (P = 0.028), anxiety (P = 0.038), and stress (P = 0.031)]. Only mild side effects were observed.

Conclusion: This study confirms the safety and clinical tolerance of atomoxetine, and its appropriate efficacy in suppressing METH craving and possible potential effects on its treatment.

Cite this article as: Rabiey A, Hassani-Abharian P, Farhad M, Moravveji AR, Akasheh G, Banafshe HR. Atomoxetine efficacy in methamphetamine dependence during methadone maintenance therapy. Arch Iran Med. 2019;22(12):692–698.
First Name
Last Name
Email Address
Security code

Abstract View: 2186

Your browser does not support the canvas element.

PDF Download: 1474

Your browser does not support the canvas element.

Submitted: 19 Nov 2018
Accepted: 16 Apr 2019
ePublished: 01 Dec 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)